Jan 25 |
Azelastine for COVID-19: real-time meta analysis of 3 studies | |
| Significantly lower risk is seen for cases and viral clearance. 3 studies from 3 independent teams in 3 countries show significant benefit. Meta analysis using the most serious outcome reported shows 21% [-3‑39%] lower risk, wi.. | ||
Jan 10 |
et al., Turkish Journal of Pharmaceutical Sciences, doi:10.4274/tjps.galenos.2024.49768 | In silico Evaluation of H1-Antihistamine as Potential Inhibitors of SARS-CoV-2 RNA-dependent RNA Polymerase: Repurposing Study of COVID-19 Therapy |
| In Silico study showing that H1RA antihistamines, including bilastine, fexofenadine, mizolastine, rupatadine, terfenadine, and the leukotriene receptor antagonists montelukast and zafirlukast, may inhibit SARS-CoV-2 RNA-dependent RNA poly.. | ||
Oct 31 |
et al., Viruses, doi:10.3390/v16121914 (date from preprint) | Azelastine Nasal Spray in Non-Hospitalized Subjects with Mild COVID-19 Infection: A Randomized Placebo-Controlled, Parallel-Group, Multicentric, Phase II Clinical Trial |
| 13% improved recovery (p=0.42) and 6% improved viral clearance (p<0.0001). RCT 294 low-risk subjects with mild COVID-19 showing significantly greater reduction in viral load with azelastine 0.1% nasal spray vs. placebo. There was no COVID-19 related hospitalization in either group. The reduction in viral load wa.. | ||
Apr 26 2023 |
et al., Scientific Reports, doi:10.1038/s41598-023-32546-z | Early intervention with azelastine nasal spray may reduce viral load in SARS-CoV-2 infected patients |
| 13% improved recovery (p=0.54) and 14% improved viral clearance (p=0.22). RCT 90 outpatients showing potential benefit of azelastine nasal spray for reducing viral load. Patients were randomized to receive placebo, 0.02%, or 0.1% azelastine nasal spray for 11 days. The 0.1% azelastine group showed greater viral.. | ||
Jan 31 2021 |
et al., Biochemical and Biophysical Research Communications, doi:10.1016/j.bbrc.2020.11.095 | Identification of antiviral antihistamines for COVID-19 repurposing |
| 45% fewer cases (p=0.03). Retrospective 219,000 patients showing lower risk of COVID-19 with antihistamine H1RA use. In Vitro study showing these drugs exhibit direct antiviral activity against SARS-CoV-2. Molecular docking suggests hydroxyzine and azelastine may .. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.